High Court Seeks US Take On Sandoz-Amgen Biosimilar Battle
The U.S. Supreme Court on Monday asked the U.S. solicitor general whether it should review a Federal Circuit ruling on the obligations of biosimilar makers, signaling that the justices are interested...To view the full article, register now.
Already a subscriber? Click here to view full article